HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b

BMC Gastroenterology

Giorgio Barbarini⁷  Caterina Furlan⁹  Angelo Barlattani^1,14  Giuseppe Barbaro³  Claudio Puoti^1,12  Umberto Vespasiani Gentilucci⁴  Olga Mitidieri^1,12  Lorenzo Nosotti⁸  Lucia Miglioresi^1,10  Cecilia D’Ambrosio^1,10  Massimo Marignani^1,13  Arnaldo Andreoli^1,10  Pascal Vignally¹  Cristina Mastropietro^1,11  Maria Elena Bonaventura^1,15  Antonio Picardi⁴  Roberto Monarca⁵  Fabrizio Mecenate^1,16  Ettore Mazzoni⁶  Tommaso Stroffolini⁹  Mario Romano²  Adriano M Pellicelli^1,10 

[1] National Institute of Health, Viale Regina Elena 299, 00161, Rome, Italy;Liver Unit Ospedale Sandro Pertini, Via dei Monti Tiburtini 385, 00157, Rome, Italy;Department of Medical Pathophysiology, University of Rome La Sapienza, Viale del Policlinico 155, 00161, Rome, Italy;Liver Unit Campus Biomedico University, Via Álvaro del Portillo, 21 00128, Rome, Italy;Infectious Disease Ospedale di Belcolle strada Sammartinese, 01100, Viterbo, Italy;Liver Unit Policlinico Casilino, Via Casilina, 1049-00169, Rome, Italy;Infectious and Parasitic Diseases, Policlinico San Matteo P.zzale Golgi,2, 27100, Pavia, Italy;Medicine of Migration National Institute for Migrant Health and Poverty, Via di S. Gallicano 25/a, 00153, Rome, Italy;Department of Infectious and Tropical Disease Policlinico Umberto I, Viale del Policlinico 155, 00161, Rome, Italy;Liver Unit Azienda Ospedaliera San Camillo Forlanini, Circonvallazione Gianicolense, 87 00149, Rome, Italy;Department of Infectious Disease Policlinico Umberto I, Viale del Policlinico 155, 00161, Rome, Italy;Department of Internal Medicine and liver unit Ospedale Generale di Marino, Viale XXIV Maggio, 00047, Marino Rome, Italy;Department of Digestive and Liver Disease, Azienda Ospedaliera Sant'Andrea, Via Grottarossa, 1035/1039, Rome, Italy;Liver Unit ASL RM/A, Rome, Italy;Infectious Disease Ospedale San Camillo de Lellis, Via John Fitzgerald Kennedy, 02100, Rieti, Italy;Liver Unit Ospedale Villa Betania, Via Niccolò Piccolomini 27, 00165, Rome, Italy

关键词: Pegylated interferon;    Antiviral therapy;    Sustained virological response;    HCV genotype 1 subtypes;    Genotype 1a;   

Others  :  858298
DOI  :  10.1186/1471-230X-12-162

 received in 2012-06-18, accepted in 2012-11-13,  发布年份 2012

【 摘 要 】

Background

The impact of viral subtype on the rate of sustained virological response (SVR) to antiviral therapy in patients chronically infected with hepatitis C genotype 1 subtype 1a and 1b has not been extensively investigated. The aim of this study is to determine whether the HCV genotype 1 subtypes 1a and 1b respond differently to treatment with PEGylated interferon (PEG-IFN) plus ribavirin.

Methods

For 48 weeks, 388 “naïve”genotype 1 patients were treated weekly with PEG-IFN α-2a or PEG-INF α-2b combined with daily ribavirin (1000–1200 mg/day). The numbers of patients in whom HCV-RNA was undetectable were compared after 4 (rapid virological response, RVR), 12 (early virological response, EVR), and 48 (end treatment virological response, ETR) weeks of treatment as well as 24 weeks after the last treatment (sustained virological response, SVR).

Results

The rate of SVR was higher in subtype 1a patients than subtype 1b patients (55% vs. 43%; p < 0.02). Multiple logistic regression analysis showed that infection with genotype 1a (odds ratio(OR) : 1.8; 95% confidence interval (CI): 1.4 to 4.1), age < 50 years (OR:7.0; 95% CI 1.1 to 21.2), alanine aminotransferase level (ALT)<100 IU/ml (OR:2.1; 95% CI: 1.3 to3.5), HCV-RNA < 5.6 log₁₀ IU/ml (OR: 3.2; 95% CI: 2.7 to 6.9) and fibrosis score < S3 (OR: 3.8; 95% CI:3.2 to 7.4), were all independent predictors of SVR.

Conclusion

Dual antiviral therapy is more effective against HCV subtype 1a than against subtype 1b and this difference is independent of other factors that may favour viral clearance.

Trial registration

ClinicalTrials.gov Identifier: NCT01342003

【 授权许可】

   
2012 Pellicelli et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]McHutchison JG, Everson GT, Gordon SC, et al.: PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009, 360:1827-1838.
• [2]Kwo PY, Lawitz EJ, McCone J, et al.: SPRINT-1 investigators. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010, 376:705-716.
• [3]Fried MW, Shiffman ML, Reddy K, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
• [4]Hadziyannis SJ, Sette H Jr, Morgan TR, et al.: PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140:346-355.
• [5]Cheng WS, Roberts SK, McCaughan G: Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. J Hepatol 2010, 53:616-623.
• [6]Bruno S, Cammà C, Di Marco V, et al.: Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial. Hepatol 2004, 41:474-481.
• [7]Rizzetto M, Colombo M, Ascione A, et al.: Effectiveness of hepatitis C virus treatment in real life practice: a prospective observational multicenter study in Italy (PROBE). J Hepatol 2008, 2(48):S311.
• [8]Legrand-Abravanel F, Colson P, Leguillou-Guillemette L, et al.: Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. J MedVirol 2009, 81:2029-2035.
• [9]Nicot F, Alric L, Barange K, et al.: Influence of genotype 1 subtypes on the virus response to Peg interferon alpha-2a plus ribavirin therapy. J Med Virol 2011, 83:437-444.
• [10]Rosina F, Tosti ME, Borghesio E, et al.: PEG-IFN for chronic hepatitis C in clinical practice: the prospective phase of the AIFA study. Dig Liv Dis 2012, 44S:s12.
• [11]Knodell RG, Ishak KG, Black WC, et al.: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981, 1:431-435.
• [12]Dienstag JL, McHutchinson J: American Gastroenterological association technical review on the management of hepatitis C. Gastroenterology 2006, 130:231-264.
• [13]Zein NN, Rakela EL, Krawitt KR, Reddy KR, Tominaga T, Persing DH: Hepatitis C virus genotypes in United States: epidemiology, pathogenicity, and response to interferon therapy. Ann Intern Med 1996, 125:634-639.
• [14]Zein NN: Clinical significance of hepatitis C virus genotypes. ClinMicrobiol Rev 2000, 13:223-235.
• [15]Nevens E, Van Vlierberghe H, D’Heygere E, et al.: BERNAR-1 Study Group. A randomized open label, multicenter studyevaluating the efficacy of peginterferon alfa 2a, in combination with ribavirin, in naïve and relapsed chronic hepatitis C patient. Acta Gastroenterol Belg 2010, 73:223-228.
• [16]Yu JW, Wang GQ, Sun LJ, Li XG, Li SC: Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J GastroenterolHepatol 2007, 22:832-836.
• [17]Sarrazin C, Zeuzem S: Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010, 138:447-462.
• [18]McHutchison JG, Lawitz EJ, Shiffman ML, et al.: Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009, 361:580-593.
• [19]Ascione A, De Luca M, Tartaglione MT, et al.: Peginterferon alfa-2a plus ribavirin is nore effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010, 138:116-122.
• [20]Rumi MG, Aghemo A, Prati GM, et al.: Randomized study of peginterferon alfa2a plus ribavirin vs peginterferon alfa2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010, 138:108-115.
• [21]Rumi MG, Aghemo A, Prati GM: Comparative trials of peginterferon alfa-2a and peginterferon alfa-2b for chronic hepatitis C. J Viral Hepatol 2012, 19:37-41.
• [22]Thompson AJ, Muir AJ, Sulkowski MS, et al.: Interleukin-28B polymorphism improves viral kinetics and is the strongestpretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010, 2010(139):120-129.